Scientists test 'Off-the-Shelf' cell therapy for tough leukemia cases
NCT ID NCT07491263
Summary
This early-stage study is testing the safety of a new type of cell therapy called QH103 for people whose B-cell leukemia has come back or hasn't responded to other treatments. The therapy uses genetically modified immune cells from a donor (not the patient) to target and fight the cancer. The main goal is to see how safe and tolerable this 'universal' CAR-T cell treatment is in a small group of patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY CD19-POSITIVE B-ALL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The first affiliated hospital of fujian medical university
Fuzhou, Fujian, 350005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.